research use only
Cat.No.S4222
| Related Targets | Integrase Bacterial Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HIV HCV Protease |
|---|---|
| Other Antibiotics Inhibitors | Puromycin G418 Sulfate (Geneticin) Nanchangmycin Sitafloxacin Hydrate Trovafloxacin Mesylate Spiramycin Nadifloxacin G-418 Gamithromycin Thiamphenicol |
|
In vitro |
DMSO
: 100 mg/mL
(185.34 mM)
Water : 100 mg/mL Ethanol : 100 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 539.54 | Formula | C23H27N5O7S.Na |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 59703-84-3 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | CL227193,Pipracil | SMILES | CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=CC=C2)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)[O-].[Na+] | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
beta-lactamase
|
|---|---|
| In vitro |
Piperacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Piperacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Piperacillin results from the inhibition of cell wall synthesis and is mediated through Piperacillin binding to penicillin binding proteins (PBPs). By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Piperacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. Piperacillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. |
References |
(data from https://clinicaltrials.gov, updated on 2026-08-12)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07759453 | NOT_YET_RECRUITING | Liver Transplant; Carbapenem-resistant Enterobacterales; CRE Colonization |
IRCCS Azienda Ospedaliero-Universitaria di Bologna |
2026-10-01 | PHASE3 |
| NCT06954129 | RECRUITING | Acute Kidney Injury |
University of Pennsylvania |
2026-01-28 | PHASE4 |
| NCT07620223 | RECRUITING | Hepatobiliary Surgery; Prophylactic Antibiotics |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2026-05-24 | |
| NCT06123169 | NOT_YET_RECRUITING | Pancreaticoduodenectomy; Antibiotherapy |
University Hospital, Rouen |
2026-07 | PHASE3 |
| NCT06184659 | RECRUITING | Sepsis; Septic Shock |
Scandinavian Critical Care Trials Group |
2025-06-26 | PHASE4 |
| NCT07556107 | RECRUITING | Infection; Acute Kidney Injury; Sepsis |
Bassett Healthcare |
2026-08-17 | PHASE4 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.